Emerging data from major clinical trials shows a new class of biologic drugs targeting the IL-33 pathway significantly reduces severe flare-ups in chronic obstructive pulmonary disease (COPD) for patients who continue to suffer exacerbations despite standard treatment, HCPLive reported. The findings offer a potential new option for a broader group of patients than current biologics, which are limited to those with specific blood inflammation markers.
This development arrives at a critical time for COPD management. While inhaled maintenance therapies form the backbone of treatment, a substantial subset of patients—particularly former smokers—experience ongoing moderate-to-severe exacerbations that worsen their prognosis and quality of life. These new trials suggest that by targeting a different inflammatory mechanism, clinicians can effectively reduce these debilitating events for a wider patient population.
The Science of IL-33: A Broad-Spectrum Target in COPD
COPD is a complex, heterogeneous disease, not a single condition. Its pathophysiology involves multiple inflammatory pathways. The biologics currently approved for COPD, such as dupilumab, primarily target a pathway known as type 2 inflammation, which is driven by high eosinophil counts in the blood. However, as Polverino explained in her presentation at the GOLD 2026 COPD International Conference, IL-33 is a distinct type of inflammatory signal, an “alarmin” produced by the bronchial epithelium itself.
“It sits upstream of the T2 inflammation… It is not a T2-only cytokine,” Polverino stated, The American Journal of Managed Care® (AJMC®) reported.
Stress to the lung lining from events like smoking, viral infections, or exacerbations can trigger the release of IL-33. This is a key difference from current treatments. Because IL-33 is “enriched in the blood and lungs of most patients with COPD, and its pathway extends beyond type 2 inflammation,” a drug targeting it could theoretically benefit a much larger portion of the patient population. Polverino estimated that only 20-30% of COPD patients have the high eosinophil counts required for existing biologics, leaving most without this advanced therapeutic option.
Phase III Trial Results: Significant Reduction in Exacerbations
The promise of IL-33 inhibition is now backed by strong data from two important Phase III trials, OBERON and TITANIA. These trials were designed to test the efficacy of an investigational monoclonal antibody, tozorakimab, in reducing COPD exacerbations. Critically, unlike previous studies for biologics, these trials did not restrict enrollment based on participants’ blood eosinophil counts, reflecting the belief that the IL-33 pathway is relevant across the spectrum of COPD inflammation.
The trials enrolled adults who were current or former smokers with a history of exacerbations despite receiving stable, guideline-recommended inhaled maintenance therapy. Participants were randomly assigned to receive the anti-IL-33 antibody or a placebo, administered via a subcutaneous injection every four weeks for one year, in addition to their usual medications.
The results were clear and clinically meaningful. The trials, as reported by EMJ Reviews, demonstrated that treatment with the IL-33-targeted antibody led to significant reductions in the annualised rate of moderate or severe exacerbations. Among former smokers, the reduction was between 29% and 34% compared to the placebo group.
In Plain English: The Clinical Takeaway
- A new injectable drug (an “anti-IL-33 biologic”) has been shown in large trials to cut down severe COPD flare-ups by nearly a third for many patients who still get sick despite using standard inhalers.
- Unlike current biologic drugs, this new treatment is not limited to patients with high eosinophil counts, meaning it could help a much wider group of people with COPD.
- The drug works by targeting a different inflammatory pathway (IL-33) that is active in most COPD patients, not just a specific subgroup, offering a new and potentially more broadly applicable approach to managing the disease.
Targeting Mucus: A Dual Mechanism and Clinical Implications
Understanding the mechanism of action for IL-33 inhibitors reveals why they may be particularly effective for a specific COPD phenotype. Research shows that IL-33 exists in two forms within the body: a reduced form that drives inflammation and an oxidized form that is primarily responsible for mucus plugging. This duality is central to the drug’s potential benefit.
Polverino highlighted that mucus plugging, visible on CT scans, is strongly associated with increased mortality and hospitalization in COPD. By targeting the IL-33 pathway, these new drugs aim to reduce both the underlying inflammation and the production of abnormal mucus. This mechanism suggests that the biologics may be especially beneficial for patients with the “chronic bronchitis” phenotype, characterized by a persistent cough and phlegm. Previously, this group had limited options beyond roflumilast and azithromycin.
However, a key biological question remains. Polverino noted that the reduced form of IL-33 can rapidly convert into the oxidized form. Current evidence cannot definitively show whether a given drug preferentially targets one form over the other. She called for further research to confirm that both forms can be effectively targeted, a step she believes is necessary before these therapies become a standard part of COPD care.
GEO-Bridging and Path to Regulatory Approval
The success of the Phase III OBERON and TITANIA trials marks a significant milestone, positioning the IL-33-targeted therapy for a potential regulatory review.
Discussing New Therapy With Healthcare Provider
While the Phase III trials reported broadly comparable adverse event rates between the treatment and placebo groups, it is essential for patients to discuss this new therapy with their healthcare provider.
Future Directions and Unanswered Questions
While the overall trial results were positive, a crucial area for future investigation is understanding whether the treatment benefits are consistent across all patient subgroups. As EMJ Reviews noted, the trials did not establish whether treatment effects varied based on specific inflammatory characteristics beyond eosinophil counts, such as blood neutrophil levels or other biomarkers. Further analyses are needed to identify which patients derive the most significant benefit from IL-33 inhibition.
The long-term effects of targeting this pathway are still being studied. The trials were 52 weeks in duration, which provides good data on efficacy and short-term safety, but longer-term follow-up will be necessary to monitor for any potential rare or delayed adverse events and to confirm the durability of the treatment’s effect on reducing exacerbations over many years.
References
- Polverino F. The duality of IL-33 in COPD: inflammation and mucus dysfunction. Presented at: GOLD 2026 COPD International Conference; November [X], 2026; Philadelphia, PA.
- Bhatt SP, Rabe KF, Martinez FJ, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024;390(24):2274-2283. doi:10.1056/NEJMoa2401304.
- Sciurba FC, Watz H, Bourdin A, et al. Tozorakimab to prevent COPD exacerbations. N Engl J Med. 2026 Oct 29;395(17):1703-1716. doi:10.1056/NEJMoa2606998.
- England E, Rees DG, Scott IC, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023;13(1):9825. doi:10.1038/s41598-023-36642-y.
